Naperol Investments turns profitable at ₹0.40 Cr PAT, margins expand sharply y/y
revenue +33.7% · margins expanding
₹3.93 Cr
+33.7% YoY
₹0.4 Cr
10.23%
+10.6pp YoY
₹0.7
Naperol Investments Limited (formerly National Peroxide Limited) — now operating purely as an investment-holding company after its hydrogen-peroxide manufacturing business was demerged into separately listed National Peroxide Ltd — posted a standalone net profit of ₹0.40 Cr for Q2 FY27, a turnaround from a ₹0.01 Cr loss a year ago. Revenue from operations rose 34% YoY to ₹3.93 Cr but fell 58% QoQ from ₹9.45 Cr in Q1 FY27, since almost all of the topline is Trading-segment churn from buying/selling securities rather than a recurring operating business. There were no exceptional items in either the current or year-ago quarter, so the YoY swing to profit is the clean, as-reported number — no raw-vs-adjusted distinction is needed here.
Q2 FY-2027 vs prior quarters
The improvement is a segment-mix story, not a scale story. The Investment segment — passive income (dividends, interest, FVTPL gains) off the company's ₹914 Cr investment book — generated ₹0.58 Cr of pre-tax profit this quarter, roughly 87% of the ₹0.66 Cr total segment result, while the Trading segment added just ₹0.08 Cr, down from ₹0.25 Cr in Q1 FY27 and versus a ₹0.02 Cr loss a year ago. Net margin (PAT/total income) expanded to ~10.2% from 1.92% in Q1 FY27 and -0.35% a year ago; operating margin (revenue less total expenses) widened to ~11.8% from 1.88% QoQ and ~1.3% YoY — both effects of this quarter's lower trading volumes needing proportionally lower stock-purchase costs, not any pricing or cost action.
The stock went into the print at ₹535, down 6.1% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
There is no management guidance on record and no prior concall read in our context to benchmark against — management gives no formal forward outlook — and a web search turned up no analyst or brokerage coverage of the stock, so the print cannot be checked against a street number; no company press release beyond the board-outcome letter was available for this quarter. The same November 11, 2026 board meeting that approved these results also appointed Mr. Vinay Divakar Jayade — currently CEO of group company National Peroxide Ltd — as an Additional Director, and Ms. Jinal Shah as Company Secretary, alongside a separate director's resignation on November 2, 2026; these are governance items unconnected to the quarter's numbers but consistent with ongoing board reconstitution post-demerger.
W1
Trading segment pre-tax profit — ₹0.08 Cr this quarter vs ₹0.25 Cr in Q1 FY27 — whether it stabilizes above the ₹0.20 Cr level given its revenue volatility.
W2
Investment segment pre-tax income, which has run ₹0.49–0.66 Cr per quarter over the trailing year; a sustained move outside that band would be the first sign of a shift in the ₹914 Cr portfolio's return profile.
W3
Any capital-allocation signal from newly appointed Additional Director Mr. Vinay Jayade (effective Nov 11, 2026), given his operating-company background versus the board's current investment-holding mandate.